Orally-inhaled beclometasone was first approved by the FDA in 1976.

The beclometasone inhalation patent expired in December 1994. Beclovent® oral inhalation aerosol is no longer manufactured, however, Vanceril® inhalation aerosol is still available in the US. Moreover, Beconase AQ® and Vancenase AQ® nasal sprays were first FDA-approved in 1987, with Vancenase AQ® double-strength being marketed in 1996.

Additionally, Qvar®, an ozone friendly, pressurized MDI, first received FDA approval in September 2000 for treatment of asthma in adults and adolescents. This particular formulation delivers smaller particle-sized medication to the airways, allowing a lower dose of beclometasone to be as efficacious as the conventional MDIs. Qvar® gained FDA-approval for use in children 5-11 years of age in May 2002.

Please visit the official site of the FDA for further information.

 

Why is this medication prescribed?

Other uses for this medicine

Dosage and using this medicine

What special precautions should I follow?

What should I do if I forget a dose?

What side effects can this medication cause?

What storage conditions are needed for this medicine?

In case of an emergency/overdose